Neuromate and Stressza as Supportive Therapy in Canine Distemper
Role of Liq. Neuromate® and Stressza® as Supportive Therapy in Canine Distemper: A Field Experience from Rampur Bushahr, Himachal Pradesh, India
Dr. Anil Kumar Sharma Veterinary Officer, Department of Animal Husbandry, Himachal Pradesh
Abstract
Canine distemper (CD) remains one of the most fatal viral diseases affecting domestic dogs and, occasionally, other carnivores including cats. The present field-based observational study was conducted in Rampur Bushahr, Himachal Pradesh, to evaluate the use of Liq. Neuromate and Liq. Stressza as supportive therapy in naturally occurring cases of canine distemper.
A total of 28 clinical cases were included in the study, comprising 26 dogs (16 males and 10 females of different age groups) and 2 cats aged approximately 6–8 months. All animals received standard symptomatic management, including fluid therapy, broad-spectrum antibiotics where indicated, antiemetics, nutritional support, anticonvulsants (when required), and nursing care. In selected neurological cases, Liq. Neuromate and Liq. Stressza were administered orally as adjunct supportive therapy. The recommended dosage was 10 drops three times daily (TID) for animals aged 6 months to 1 year, and 20 drops TID for animals older than one year.
Among the 10 dogs that received Neuromate and Stressza in addition to conventional therapy, 3 dogs recovered completely, while the remaining succumbed to the disease. Both cats received the same supportive protocol; one cat recovered successfully, whereas one died despite intensive treatment.
Although the sample size was limited and no control group was included, the observed recovery in some neurologically affected animals suggests that Neuromate and Stressza may have potential value as adjunct supportive agents during canine distemper management. Their possible neuroprotective, antioxidant, and stress-relieving properties may contribute to improved clinical outcomes when combined with aggressive symptomatic treatment and nursing care.
This preliminary field experience highlights the need for well-designed randomized controlled clinical trials involving larger sample sizes to scientifically evaluate the efficacy of these supportive formulations in canine distemper. Until such evidence is available, Neuromate and Stressza should be considered only as supportive adjuncts rather than replacements for established symptomatic therapy.
Keywords: Canine distemper, supportive therapy, Neuromate, Stressza, neurological distemper, dogs, cats, field study, Rampur Bushahr, Himachal Pradesh.
Introduction
Canine distemper is one of the most important infectious diseases affecting domestic dogs worldwide. The disease is caused by the Canine Distemper Virus (CDV), an enveloped, negative-sense RNA virus belonging to the family Paramyxoviridae. Besides dogs, the virus infects numerous wild carnivores and occasionally felids, causing severe multisystemic disease.
Clinical manifestations vary depending upon the immune status and age of the affected animal. Initial signs commonly include fever, ocular and nasal discharge, anorexia, coughing, vomiting, diarrhoea, and respiratory distress. In many animals, the disease progresses to neurological involvement characterized by myoclonus, seizures, circling, ataxia, paresis, paralysis, and behavioural abnormalities. Neurological distemper is associated with a poor prognosis, and mortality remains high despite intensive treatment.
Currently, there is no specific antiviral drug proven to eliminate CDV infection. Consequently, treatment focuses on supportive care aimed at maintaining hydration, controlling secondary bacterial infections, reducing inflammation, managing seizures, improving nutritional status, and minimizing stress.
Because neurological damage contributes significantly to mortality, supportive formulations that may enhance neuronal function and reduce physiological stress are of considerable clinical interest.
Liq. Neuromate® is marketed as a nutritional supplement intended to support neurological health, whereas Liq. Stressza® is used to alleviate stress and improve recovery during illness. However, published scientific evidence regarding their clinical application in canine distemper remains limited. The present study documents field observations on their use in naturally occurring cases managed under routine veterinary practice.
Materials and Methods
Study Area
The study was conducted at Rampur Bushahr, District Shimla, Himachal Pradesh, India, during routine veterinary clinical practice. Cases were presented either directly by pet owners or through animal welfare organizations.
Study Population
A total of 28 naturally occurring clinical cases of canine distemper were included.
The study population consisted of:
26 dogs
- 16 males
- 10 females
- Various age groups
2 cats
- Approximately 6–8 months of age
Animals represented different breeds as well as non-descript dogs.
Diagnosis
Diagnosis was based primarily on clinical examination and history. Common clinical findings included:
- Fever
- Bilateral ocular discharge
- Nasal discharge
- Respiratory distress
- Anorexia
- Vomiting
- Diarrhoea
- Myoclonus
- Ataxia
- Muscle twitching
- Convulsions
- Progressive neurological signs
Cases exhibiting characteristic neurological manifestations consistent with canine distemper were included in the observational study.
Treatment Protocol
All animals received standard symptomatic treatment according to clinical presentation, including:
- Intravenous fluid therapy
- Broad-spectrum antibiotics to control secondary bacterial infections
- Antiemetics
- Vitamin supplementation
- Nutritional support
- Anticonvulsant therapy whenever indicated
- Intensive nursing care
- Maintenance of hydration and body temperature
In selected neurological cases, Liq. Neuromate® and Liq. Stressza® were administered orally as adjunct supportive therapy.
Dosage
Animals aged 6 months to 1 year
- 10 drops orally, three times daily (TID)
Animals older than 1 year
- 20 drops orally, three times daily (TID)
Treatment continued according to the clinical response and survival of the patient.
Results
Among the total 28 clinical cases, 10 dogs received Liq. Neuromate and Liq. Stressza in addition to conventional supportive therapy.
Of these:
- 3 dogs survived and gradually recovered from neurological signs.
- 7 dogs died despite intensive treatment.
Both cats included in the study also received Neuromate and Stressza.
Among the cats:
- 1 cat survived
- 1 cat died
The overall observations are summarized below.
| Species | Total Cases | Received Neuromate + Stressza | Survived | Died |
|---|---|---|---|---|
| Dogs | 26 | 10 | 3 | 7 |
| Cats | 2 | 2 | 1 | 1 |
Recovered animals demonstrated gradual improvement in appetite, activity level, gait, and reduction in neurological manifestations over time. Animals that failed to recover generally exhibited progressive neurological deterioration despite intensive supportive management.
Discussion
Canine distemper continues to present a significant therapeutic challenge because no antiviral treatment capable of eliminating CDV is currently available. Survival largely depends upon immune response, severity of neurological involvement, early diagnosis, and quality of supportive care.
The present field observations indicate that Liq. Neuromate and Liq. Stressza can be safely administered alongside conventional therapy without apparent adverse effects. Recovery observed in three dogs and one cat suggests that these supportive formulations may have a beneficial role in selected patients.
Neurological recovery in canine distemper depends on limiting neuronal damage and supporting regeneration wherever possible. Nutritional supplements containing neuro-supportive ingredients may improve neuronal metabolism, while stress-reducing formulations may contribute to improved appetite, reduced physiological stress, and better overall recovery.
Nevertheless, interpretation of the present findings should be undertaken cautiously. Since canine distemper exhibits variable clinical severity, spontaneous survival cannot be excluded. The absence of laboratory confirmation, randomization, untreated controls, and statistical analysis limits conclusions regarding efficacy.
Field studies conducted under routine veterinary conditions often provide valuable preliminary information that can guide future research. The encouraging survival observed in some animals warrants controlled clinical trials involving larger populations, laboratory confirmation of disease, standardized neurological scoring systems, and long-term follow-up.
Conclusion
The present observational study documents the field use of Liq. Neuromate® and Liq. Stressza® as adjunct supportive therapy in naturally occurring canine distemper cases managed at Rampur Bushahr, Himachal Pradesh.
Among ten dogs receiving these formulations, three survived, while one of two treated cats recovered successfully. Although these observations cannot establish a causal treatment effect, they suggest that Neuromate and Stressza may serve as useful supportive supplements when combined with intensive symptomatic therapy, fluid therapy, nutritional management, and nursing care.
Further randomized controlled clinical studies with larger sample sizes are required before definitive recommendations regarding their efficacy can be made.
Limitations of the Study
- Small sample size.
- Observational field study without randomization.
- No untreated or placebo control group.
- Diagnosis based mainly on clinical findings.
- Lack of statistical analysis.
- Long-term neurological follow-up was not performed.
Acknowledgements
The author acknowledges the support of Dr. Goel’s , Goel ( Vet.) Pharma Pvt. Ltd. for helping with inputs / samples for conducting this study. I also extend my gratitude to the Department of Animal Husbandry, Himachal Pradesh, pet owners, and animal welfare volunteers of Humane People NGO who assisted in the management and follow-up of canine distemper cases included in this field study.
Conflict of Interest
The author declares no conflict of interest.
Funding
No external funding was received for this study.